Latest Updates on Yaz Settlements from Bayer
Los Angeles, CA (PRWEB) November 10, 2012
German drug maker Bayer has indicated to shareholders in its latest financial report that it will reserve an additional $262.5 million to settle Yaz and Yasmin lawsuits over blood clots, according to Dow Jones staff writer Friedrich Geiger on October 30, 2012 in an article for 4-traders.com.
The news follows a previous Bloomberg report on July 31st that Bayer would set aside $610 million to settle more Yaz cases at that time, for an average of nearly $212,000 per case. The report also stated Yaz settlements would be limited to cases involving blood clot injuries.
Anyone who suffered a blood clot, DVT, stroke or Pulmonary Embolism and believes it may be attributed to Yaz or Yasmin is urged to contact the Yaz Resource Center or speak with a lawyer about their legal options.
Last month, the American College of Obstetricians and Gynecologists issued a new warning on the safety of birth control pills containing drospirenone like Yaz and Yasmin. According to the Chicago Tribune on October 24th, the group warned these drugs may have a higher risk of causing blood clots.
On October 25, 2011, the British Medical Journal published a study from the University of Copenhagen linking the hormone in Yaz to blood clots. On October 27, 2011, the FDA released its own study entitled "Combined Hormonal Contraceptives and the Risk of Cardiovascular Disease Endpoints" showing drugs like Yaz could increase the risk of blood clots, DVT and pulmonary embolism by as much as 74%.
Trackback from your site.